PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study
about
Interventions for actinic keratosesNonsurgical innovations in the treatment of nonmelanoma skin cancerUsefulness of Photodynamic Therapy as a Possible Therapeutic Alternative in the Treatment of Basal Cell CarcinomaHow to treat actinic keratosis? An updateCancer wars: natural products strike backOxidation and cyclization of casbene in the biosynthesis of Euphorbia factors from mature seeds of Euphorbia lathyris LPharmacotherapy of actinic keratosis.Actinic keratosis: rationale and managementThe skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.A randomized, double-blind, placebo-controlled clinical trial evaluating Dermytol(®) cream for the treatment of actinic keratoses.Actinic keratosis: update on field therapy.Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cellsCost-utility of first-line actinic keratosis treatments in FinlandMethods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis -International League of Dermatological Societies in cooperation with the European Dermatology Forum.IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate.Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate.New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel.The role of ingenol mebutate in the treatment of actinic keratoses.Optimal treatment of actinic keratoses.Preventative topical diclofenac treatment differentially decreases tumor burden in male and female Skh-1 mice in a model of UVB-induced cutaneous squamous cell carcinomaAn Investigator-initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses on Dorsal Hands and Forearms.An update on nonmelanoma skin cancer.Current and emerging treatment strategies for the treatment of actinic keratosis.Diclofenac gel in the treatment of actinic keratoses.Specifying protein kinase C functions in melanoma.Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients.Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring.Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents.Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.Ingenol mebutate: a succinct review of a succinct therapyA brief review of the application and pharmacology of ethnomedicines of Indigenous Australians.Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicityComparison of the Treatment Guidelines for Actinic Keratosis: A Critical Appraisal and Review.The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers.Ingenol mebutate: A novel topical drug for actinic keratosisNatural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive AgentsIngenol mebutate for the treatment of actinic keratosis: effectiveness and safety in 246 patients treated in real-life clinical practice.Pharmacoeconomy of drugs used in the treatment of actinic keratoses.
P2860
Q24202407-E7336855-6F63-47A1-8F01-A5BEB62CDA6BQ24632006-B3A76C42-244B-443C-AFBE-D3D97B41242EQ26783084-92C71F13-8591-436F-9353-0414A20626E0Q26799944-FE4FAC38-404F-44EB-A35A-52C1C73E8EB1Q26850074-8B1CDC83-F198-41AA-BD8A-2F25C1059643Q28828621-B60298E1-64C8-4BFF-8AF9-DB3F2F560AF1Q30898080-7F884971-7372-4475-A865-097C4B66C862Q33785049-2A94ADD1-DE8D-4DB4-91EA-4F80BE0008EEQ33891947-95432DE5-0DDE-4E78-8100-DDA5D6A5E000Q34042647-4DD3BA2E-1BC6-4364-B41E-DE1E2F972B3CQ34441431-EDC485F6-E906-43AA-A81A-720EA469DC7DQ34781362-DEB3A68D-6BBF-48CC-AB95-35ADFFC6CAC4Q35666250-81ECB5DA-6E93-40ED-88A8-7CD4B263110AQ35767304-97CC92E2-0D09-4C48-9C3D-48D016E4A7B7Q35996041-C2E95032-E826-4F7B-9E8F-EDB2E0CF54CEQ36128569-123605A9-7792-4FBF-92D1-8B940C0E94EBQ36196699-D87EAA38-B0B9-418D-BD75-4C336D01FE2DQ36434826-68CC86FF-CCB2-4E32-B363-35D3A37B4555Q36547571-05748409-45A3-4564-801F-4687BD36A67EQ36587639-120C8C61-4C79-4285-BD5C-387EDF295308Q36630030-EEA22FAE-185F-4735-8080-E68C02498D49Q37851020-210227D5-C680-4162-8425-39A3C36F05F0Q37857684-F9075F65-80C6-4A9D-AF01-826EA074141FQ37900834-728A5F5B-BEC4-4453-BC51-F670F123DF58Q38009398-0DB78352-97C6-44BE-BBF3-BC68D2ED36E3Q38010633-34A35882-8FDF-479C-BC00-E9047EA318A8Q38066531-2D27E7CF-0BD0-45D5-9C5E-02AF6019E070Q38101606-391EF20E-20B2-4EB3-9110-6E859E5DE05CQ38103795-4DF30A63-92F1-440F-B1ED-9E7E8820A526Q38106805-209B68AC-6C51-41EF-B7F9-8048A987D711Q38243602-2C923B20-260B-4368-834D-AB859250F422Q38600115-CBDAAEC4-419C-40B2-A6D9-F46404D7E0C6Q38622474-978BA451-9E95-460A-AA00-B6610E93549EQ38913840-CC274C10-9D69-42BE-8C13-2CAD384775C0Q39311286-A71A77DD-CB65-4BBA-8EAB-74E672E24ABCQ42484803-4F189B30-1640-4402-9A5B-FA651F039560Q42567165-37D0BBBE-A131-488A-BC75-4E2483FE39A1Q42755952-A789F49F-3A94-4AC8-B93E-143E5CEA211DQ47626283-D0562D6C-0859-4E1B-B28F-F54310204585Q47743857-8AB03F80-AA50-41E5-959C-B96D3E38C71B
P2860
PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
PEP005 (ingenol mebutate) gel, ...... , multicentre, phase IIa study
@ast
PEP005 (ingenol mebutate) gel, ...... , multicentre, phase IIa study
@en
PEP005 (ingenol mebutate) gel, ...... , multicentre, phase IIa study
@nl
type
label
PEP005 (ingenol mebutate) gel, ...... , multicentre, phase IIa study
@ast
PEP005 (ingenol mebutate) gel, ...... , multicentre, phase IIa study
@en
PEP005 (ingenol mebutate) gel, ...... , multicentre, phase IIa study
@nl
prefLabel
PEP005 (ingenol mebutate) gel, ...... , multicentre, phase IIa study
@ast
PEP005 (ingenol mebutate) gel, ...... , multicentre, phase IIa study
@en
PEP005 (ingenol mebutate) gel, ...... , multicentre, phase IIa study
@nl
P2093
P3181
P1476
PEP005 (ingenol mebutate) gel, ...... , multicentre, phase IIa study
@en
P2093
Greg Siller
Janelle Katsamas
Kurt Gebauer
Peter Welburn
P3181
P356
10.1111/J.1440-0960.2008.00497.X
P407
P577
2009-02-01T00:00:00Z